Today: 29 January 2026
Subscribe
Browse Category

NASDAQ:ARWR News 30 December 2025 - 7 January 2026

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

New York, Jan 7, 2026, 12:57 (EST) — Regular session Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE. The spark this week came from Arrowhead Pharmaceuticals, which on Tuesday posted interim results from its obesity…
7 January 2026
·····
Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

New York, Jan 6, 2026, 11:34 AM EST — Regular session Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors The update…
6 January 2026
···
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

New York, Jan 5, 2026, 13:31 EST — Regular session Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener The clearance gives Arrowhead another regulated market for its first commercial product, as…
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

NEW YORK, December 30, 2025, 13:47 ET — Regular session Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95. The stock’s drop came as biotech weakened but the wider market held steady, a setup that can amplify moves in higher-volatility drug developers. The SPDR S&P Biotech ETF…
30 December 2025
····

Stock Market Today

  • Stocks Mixed as Fed Holds Interest Rates Steady, Nasdaq Hits 3-Month High
    January 29, 2026, 12:45 AM EST. Stocks closed mixed on Wednesday after the Federal Reserve (Fed) kept interest rates at 3.50%-3.75%, in line with expectations. The S&P 500 fell slightly from a record high, down 0.01%, while the Nasdaq 100 jumped 0.32% to a three-month peak, buoyed by gains in chipmakers and AI infrastructure stocks. ASML Holding posted record Q4 bookings of 13.2 billion euros, fueling optimism in semiconductor equipment demand. Better-than-expected earnings from Seagate and Texas Instruments also supported market sentiment. The dollar index rebounded after a recent plunge, influenced by President Trump's comments, which also pushed gold prices to a new peak. Meanwhile, oil prices rose to a four-month high amid geopolitical tensions with Iran. Mortgage applications declined by 8.5% last week as the average 30-year mortgage rate increased to 6.24%. The Fed signaled a wait-and-see approach on future rate changes, citing steady economic growth and inflation risks.
Go toTop